Natural Killer Cells explained by NantKwest | NK-92 for aNK, haNK, and taNK
For years, many considered it a longshot. In fact, we’ve been calling it a moon shot. But that hardly does us justice. With recent discoveries in molecular science and rapid advancements in supercomputing technology, we are now on the path that will forever change the way cancer is diagnosed and treated. It is no longer a dream—no longer just an aspiration. It is a forging of breakthroughs, long overdue in the fight against cancer, that are giving millions hope that will subdue cancer by harnessing the most powerful defense against this deadly disease—one’s own immune system. This tectonic shift in the way cancer has been treated is deserving of its own, more fitting name—a name that celebrates its progress, promise, and forward momentum. We’re calling it Cancer Breakthroughs 2020.
NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. – less